Skip to main content
Apimeds Pharmaceuticals US, Inc. logo

Apimeds Pharmaceuticals US, Inc. — Investor Relations & Filings

Ticker · APUS US Manufacturing
Filings indexed 109 across all filing types
Latest filing 2026-05-04 Annual Report
Country US United States of America
Listing US APUS

About Apimeds Pharmaceuticals US, Inc.

https://www.apimedsus.com/

Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company focused on developing its lead product candidate, Apitox. This non-opioid, biologic drug is derived from bee venom and is intended for intradermal administration to treat pain associated with osteoarthritis of the knee. Following a merger with MindWave, the company has integrated its biotechnology development with a focus on AI-driven digital treasury and yield generation solutions.

Recent filings

Filing Released Lang Actions
10-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
Annual Report
2026-05-04 English
8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
Regulatory Filings
2026-05-04 English
8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
Regulatory Filings
2026-04-22 English
8-K/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
Regulatory Filings
2026-04-09 English
SCHEDULE 13D/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Subject)
Major Shareholding Notification
2026-03-30 English
8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
Regulatory Filings
2026-03-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.